Current reimbursement models in general do not accommodate many of the unique factors common among gene and cell therapies. In this second article of a three-part series, CRA’s Walter Colasante, Pascale Diesel, and Lev Gerlovin discuss the challenges to demonstrating value and addressing affordability and discuss options for payment models.
The authors wish to acknowledge the contributions of Stephanie Donahue and Michael Krepps to this article.
Click here to read the article.
Cécile Matthews quoted in Pink Sheet article following study on non-oncology orphan drug pricing in France
Following a recent study on non-oncology orphan drug pricing in France, CRA’s Cécile Matthews was interviewed by reporter Francesca Bruce. The interview was...